DTDuygu Tozcu

Duygu Tozcu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Duygu Tozcu has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • İnsan Fizyolojisinin Bütüncül Dinamikleri

    by İlKnur Karakaya, Ayşe Bulut, Mehtap Şahin, Duygu Tozcu Yılmaz, Kamil Duran, Fethi Ahmet Uğur

    Tıp ve sağlık bilimlerinin hızla değişen doğasında, teorik fizyoloji birikimini klinik pratikle harmanlayan bu eser; sirkadiyen ritimden hücresel adaptasyona, özel doku fizyolojisinden modern egzersiz metodolojilerine kadar tıbbın ve spor bilimlerinin en kritik alanlarını multidisipliner bir perspektifle ele almaktadır. Kitapta; yaşamın en temel zamanlama mekanizması olan sirkadiyen ritmin yapısından başlayarak, iç dengenin korunmasında hayati rol oynayan homeostasisin dinamik regülasyon prensipleri ve hareketin moleküler mimarı olan iskelet kasının temel yapısı incelenmektedir. Egzersiz fizyolojisinde iskelet kasının akut ve kronik yüklenmelere karşı verdiği dinamik yanıtlar detaylandırılırken; son yıllarda performans ve rehabilitasyonda çığır açan kan akışı kısıtlamalı egzersiz (BFR) metodolojisi kanıta dayalı verilerle ele alınmıştır. Ayrıca, yaşam kalitesini ve insan sağlığını doğrudan etkileyen yaşlanma fizyolojisi ile bu sürecin kritik bir bileşeni olan prostatın önemi güncel literatür ışığında sunulmuştur. Nihayetinde tüm bu teorik temel, bütüncül bir yaklaşımla egzersiz fizyolojisindeki klinik uygulamalar düzleminde somutlaştırılmıştır. Bilimsel titizlikle hazırlanan bu çalışma; tıp, fizyoterapi ve spor bilimleri alanında eğitim gören öğrencilere, uzmanlık eğitimi alan asistanlara ve ayrıca deneyimli akademisyen ile uzman hekimlere rehberlik edecek kapsamlı bir başvuru kaynağı niteliğindedir.

  • Open Access

    Reduced Aqueous Humor TGF-β2 Levels in Diabetic Cataract: A Comparative Analysis with NF-κB

    by Duygu Tozcu Yilmaz, Mehmet Ali Gul, Mustafa Capraz, Melek Tufek, Nihat Aydin

    Background/Objectives: Type 2 diabetes may impair anterior segment immune regulation. Because transforming growth factor-β2 maintains ocular immune privilege, while nuclear factor-κB is linked to inflammatory activation, we compared their aqueous humor levels in cataract patients with and without diabetes. Methods: In this prospective cross-sectional study, aqueous humor samples were collected from 90 patients (30 diabetic, 60 non-diabetic) via anterior chamber needle aspiration at the commencement of routine phacoemulsification, prior to viscoelastic injection, without additional intervention. Transforming growth factor-β2 and nuclear factor-κB levels were then measured using enzyme-linked immunosorbent assay (ELISA). Between-group comparisons and ROC curve analyses were performed to evaluate differences in biomarker levels and their discriminative ability in distinguishing diabetic status. Covariate-adjusted analysis (ANCOVA) was additionally performed. Results: Transforming growth factor-β2 levels were significantly lower in the diabetic group (p < 0.001), while nuclear factor-κB levels showed no significant difference (p = 0.285). The between-group difference in transforming growth factor-β2 remained significant after adjustment for cataract grade and hypertension duration (F(1,86) = 17.901, p < 0.001, partial η2 = 0.172; Cohen’s d = 0.94). Transforming growth factor-β2 demonstrated high specificity (100%) but limited sensitivity (45%) for identifying diabetic status at a cut-off of <449.25 ng/L; however, given the small sample size and exploratory nature of the study, this specificity value should be interpreted with caution and requires validation in larger cohorts. Conclusions: Lower aqueous humor TGF-β2 levels in diabetic cataract patients, independent of cataract severity and hypertension duration, suggest that TGF-β2 suppression may represent an earlier molecular event in anterior segment immune dysregulation preceding overt inflammatory activation. While TGF-β2 shows exploratory biomarker potential, validation in larger, prospective, mechanistic studies is required before clinical application.

  • Serum Preptin as a Potential Biomarker for Metabolic Syndrome and Insulin Resistance

    by Gamze Turna Saltoglu, Erkan Dulkadiroglu, Duygu Tozcu Yilmaz, Bilal Ilanbey, Ulken Tunga Babaoglu

    Introduction: Metabolic syndrome (MetS) is a complex condition involving obesity, hyperglycemia, dyslipidemia, and hypertension. Preptin, a novel molecule co-secreted with insulin from pancreatic β-cells, has been suggested to play a role in insulin resistance and glucose and lipid metabolism. This study aimed to evaluate the differences in serum preptin levels between healthy controls and MetS patients, and to investigate its relationship with clinical parameters. Material and methods: The study included forty MetS patients and forty age- and sex-matched healthy controls. Demographic and clinical data were collected, the serum preptin levels were measured by Enzyme-Linked Immunosorbent Assay (ELISA). The relationships between the serum preptin levels and clinic parameters were assessed. Results: Serum preptin levels were significantly higher in MetS patients compared to the control group (53.77 pg/mL vs. 40.77 pg/mL, p<0.001). MetS patients also had higher triglyceride, cholesterol, low-density lipoprotein cholesterol (LDL-C), fasting glucose, Hemoglobin A1c (HbA1c), insulin, and Homeostatic model assessment of insulin resistance (HOMA-IR) values compared to controls (all p<0.001). A positive correlation was found between serum preptin, insulin (r=0.432, %95 CI:0.07-0.57, p=0.0050), and HOMA-IR (r=0.426, %95 CI:0.08-0.56, p=0.0060) in the MetS group. Conclusions: The results indicate that serum preptin levels are significantly elevated in MetS patients. Furthermore, high serum preptin levels were positively correlated with insulin and insulin resistance. These results suggest that preptin may be involved in the insulin resistance pathway via insulin-like growth factor II (IGF-II) modulation. Therefore, further extensive studies are required to fully understand the precise role in MetS and underlying mechanisms of preptin.

  • Open Access

    Investigation of Serum Visfatin and Chemerin Levels in Type 2 Diabetes and Obesity Patients: Their Potential Role as Clinical and Biomarkers

    by Duygu Tozcu Yilmaz, Mehmet Ali Gul, Mustafa Capraz, Hatice Dortok Demir, Akin Tekcan

    Background/Objectives: The global prevalence of obesity and type 2 diabetes mellitus (T2DM) has been steadily increasing, and these interrelated disorders share common pathophysiological mechanisms, including altered levels of adipokines secreted from adipose tissue. Among these, chemerin and visfatin have been suggested as potential biomarkers for obesity-related metabolic dysfunction. This study aimed to evaluate the relationship between serum chemerin and visfatin levels and obesity in patients with T2DM. Methods: The study included 74 obese T2DM patients, 60 non-obese T2DM patients, and 36 healthy controls. Serum chemerin and visfatin levels were measured using an enzyme-linked immunosorbent assay (ELISA). Clinical parameters including HbA1c, fasting plasma glucose, insulin, and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) were assessed. Between-group comparisons were performed using appropriate parametric or non-parametric tests with Bonferroni correction for multiple comparisons. ROC curve analysis was applied to evaluate the diagnostic performance of visfatin. Results: Serum visfatin levels were significantly higher in the T2DM (33.00 ± 20.61) groups compared to controls (30.25 ± 26.40; p = 0.01), while chemerin levels showed no significant difference. HbA1c and glucose levels were elevated in both diabetic groups, whereas insulin and HOMA-IR were significantly higher only in the obese T2DM group. Receiver operating characteristic (ROC) analysis revealed limited diagnostic accuracy of visfatin (AUC < 0.70). Conclusions: Visfatin levels were modestly higher in obese T2DM patients, while chemerin did not differ significantly among groups. However, the diagnostic performance of visfatin was limited (AUC < 0.70), and these findings should be regarded as exploratory. Larger, well-controlled studies are required to clarify whether visfatin or chemerin could have any clinical utility as part of multi-marker approaches.


  • SERUM ASPROSİN DÜZEYLERİ İLE NONPROLİFERATİF VE PROLİFERATİF DİYABETİK RETİNOPATİ ARASINDA BİR İLİŞKİ VAR MIDIR?

    by Nihat Aydın, Melek Tüfek, Mustafa Çapraz, Duygu Tozcu Yılmaz, Mehmet Ali Gül

    Amaç: Çalışmamızdaki amacımız serum asprosin seviyelerinin diyabetik retinopati (DR) patogenezindeki rolünü araştırmak ve diyabetin farklı evreleri için olası farklılıkları ortaya koymaktı. Yöntem: Bu prospektif çalışmaya Tip 2 diyabetes mellitus (T2DM)’lu, 32 nonproliferatif diyabetik retinopati (NPDR), 28 proliferatif diyabetik retinopati (PDR) hastası ile 30 sağlıklı birey dahil edildi. Tüm katılımcıların antropometrik ölçümleri yapıldı. Biyokimyasal parametreler değerlendirildi. Serum asprosin seviyeleri enzyme-linked immunosorbent assay (ELISA) yöntemi kullanılarak analiz edildi. Bulgular: Açlık kan glukozu (AKG), insülin, insülin direncinin homeostaz modeliyle değerlendirmesi (HOMA-IR), hemoglobin A1c (HbA1c), trigliserid ve vücut kitle indeksi (VKİ) değerleri; DR gruplarında kontrol grubuna göre istatistiksel açıdan anlamlı derecede daha yüksek bulundu (p

  • Open Access

    The Role of ADAM9 and MMP9 in Diabetic Retinopathy: Insights from Ocular Parameters

    by Mehmet Ali Gul, Duygu Tozcu Yilmaz, Nihat Aydin, Melek Tufek, Mustafa Capraz

    The focus in this study was to investigate the proteolytic functions of matrix metalloproteinases (MMPs) and a disintegrin and metalloprotease (ADAM) proteins in the progression of diabetic retinopathy (DR) and to evaluate their potential as therapeutic targets for eye diseases. This study involved three groups: non-proliferative diabetic retinopathy patients (NPDR) (n = 27), proliferative diabetic retinopathy patients (PDR) (n = 32), and a control group of 30 healthy individuals. Serum levels of ADAM9 and MMP9 were measured across these groups for comparative analysis. Serum ADAM9 levels were significantly lower in the NPDR and PDR groups than in the control group (p = 0.031, p < 0.001). Although ADAM9 levels were lower in the PDR group than in the NPDR group, this difference was not significant (p = 0.142). Serum MMP9 levels in the PDR group were significantly lower than those in both the control and NPDR groups (p = 0.039, p = 0.013). The findings of this study indicate that ADAM9, MMP9, and left-eye ocular parameters may have potential value in the assessment of DR. The notable variation in the MMP9 marker in the proliferative stage, as opposed to its stability in the non-proliferative stage, suggests a distinct role in retinopathy staging. This underscores the specific importance of MMP9 in the proliferative stage.


  • Open Access

    Investigation of Inflammation Rates (Neutrophil/Lymphocyte) and Hemogram Results in the Stages of Non-Alcoholic Fatty Liver Disease

    by Mehmet Ali Gül, Duygu Tozcu Yılmaz, Mustafa Çapraz

    Introducton: Non-alcoholic fatty liver disease (NAFLD) is a chronic condition characterized by excessive fat accumulation in the liver accompanied by inflammation. This study aims to know the diagnostic value of NLR in stages of NAFLD Methods: A retrospective case-control study was conducted, including 49 NAFLD patients with NAFLD Grade 1, 48 with NAFLD Grade 2, 52 with NAFLD Grade 3, and 103 healthy control (HC) individuals. Neutrophil/Lymphocyte ratios as well as RBC, HGB, HCT, MCHC, MPV, WBC, MCV, MCH, PLT, RDW-SD, RDW-CV, PDW, PCT, NEUT#, LYMPH%, NLR, MONO%, EO%, BASO% values were examined. Results: As the disease stages progressed (G3), a significant decrease (p=0.005*) in MPV values and a significant increase (p0.05), MCH (p>0.05), PDW (p>0.05), PCT (p>0.05), MONO (p>0.05) and EO (p>0.05) parameters. Conclusion: MPV and NLR may be considered as effective biomarkers for monitoring the progression of NAFLD and evaluating the inflammatory status of patients.

  • Open Access

    Effects of Resveratrol on the Kidney in Rats with Streptozotocin Induced Diabetic Nephropathy

    by Duygu Tozcu, Çiğdem Özer, Aydan Babül, Sevim Ercan, Ergin Dileköz, Gülnur Take Kaplanoğlu, Güleser Göktaş

    Effects of Resveratrol on the Kidney in Rats with Streptozotocin Induced Diabetic Nephropathy - Gazi Medical Journal


  • Open Access

    Investigation of the rs7041 variable of vitamin D-connector protein gene relation with pancreatic involvement in patients with coronavirus disease 2019

    by Vuslat Öztürk, Mehmet Ali Gül, Recai Aci, Âdem Keskin, Duygu Tozcu, Mustafa Cihangiroğlu, Muhammed Taha Kaya, Mustafa Çapraz, Serbülent Yiğit, Akιn Tekcan

    OBJECTIVE: This study aims to examine whether the presence of mutation exists in the vitamin D-connector protein gene rs7041 variant of the pancreatitis table for patients diagnosed with coronavirus disease 2019.


  • Open Access

    Immediate effects of manual therapy on respiratory functions in healthy young individuals: a randomized controlled trial

    by Eylem Küçük, Duygu Tozcu, Berkhan Topaktaş, Gürsoy Coşkun

    This study aimed to investigate the immediate effects of manual therapy (MT) on the respiratory functions of healthy young individuals. The study included 104 participants, consisting of university students (87 females, 17 males, mean age 20.1 ± 2.2). Participants were randomly assigned to the MT (experimental; n = 52) and sham-MT (control; n = 52) groups. The experimental group underwent thoracic manipulations and mobilizations along with diaphragm mobilization. In the control group, the hands were placed on the same regions, but no specific intervention was applied. All participants underwent respiratory function testing before and after the intervention using a portable spirometer (PEF- Peak expiratory flow; FEV 1- Forced expiratory volume in 1 s; FVC- Forced vital capacity and FEV1/FVC- Tiffeneau index). In the experimental group, there was a significant increase in the mean PEF value following MT application from 296.3 ± 110.8 to 316.1 ± 119.1 (p = 0.018). Conversely, the mean PEF value in the control group showed a slight decrease from 337.1 ± 93.3 to 324.5 ± 89.2 (p = 0.002). No significant changes were observed in FVC, FEV1, or FEV1/FVC values pre- and post-intervention in either groups. A single MT session led to a significant improvement in PEF in healthy young individuals. Further research is needed to explore the long-term effects of MT on respiratory functions and its potential implications in clinical practice. Trial registration ClinicalTrials.gov: NCT05934240 (06/07/2023).